Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNFT NASDAQ:MGTX OTCMKTS:OSIR NASDAQ:OYST NASDAQ:RUBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNFTGENFIT$3.65-2.7%$4.10$2.55▼$6.42$187.51M1.0810,427 shs5,487 shsMGTXMeiraGTx$8.47-1.7%$6.16$3.85▼$8.75$692.75M1.24404,580 shs519,251 shsOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/AOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsRUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNFTGENFIT-2.67%-4.45%-14.12%+7.67%-16.34%MGTXMeiraGTx-1.74%+12.86%+30.71%+62.88%+104.59%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNFTGENFIT2.3147 of 5 stars3.55.00.00.02.10.00.0MGTXMeiraGTx4.258 of 5 stars3.51.00.04.83.22.50.6OSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNFTGENFIT 3.00Buy$13.00256.16% UpsideMGTXMeiraGTx 3.00Buy$24.00183.35% UpsideOSIROsiris Therapeutics 0.00N/AN/AN/AOYSTOyster Point Pharma 0.00N/AN/AN/ARUBYRubius Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MGTX, RUBY, GNFT, OYST, and OSIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNFTGENFIT$76.77M2.38$0.07 per share53.61$1.50 per share2.43MGTXMeiraGTx$33.28M20.45N/AN/A$0.87 per share9.74OSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/AOYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94RUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)MGTXMeiraGTx-$147.79M-$2.32N/A22.29N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)OSIROsiris TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AOYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/ARUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ALatest MGTX, RUBY, GNFT, OYST, and OSIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGTXMeiraGTx-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNFTGENFITN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNFTGENFIT0.081.231.23MGTXMeiraGTx2.341.531.51OSIROsiris TherapeuticsN/AN/AN/AOYSTOyster Point Pharma8.493.353.11RUBYRubius TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNFTGENFIT2.24%MGTXMeiraGTx67.48%OSIROsiris Therapeutics0.28%OYSTOyster Point Pharma96.70%RUBYRubius TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipGNFTGENFIT4.20%MGTXMeiraGTx7.50%OSIROsiris Therapeutics43.40%OYSTOyster Point Pharma17.90%RUBYRubius Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableMGTXMeiraGTx30080.36 million74.34 millionOptionableOSIROsiris Therapeutics34234.53 millionN/ANot OptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableMGTX, RUBY, GNFT, OYST, and OSIR HeadlinesRecent News About These CompaniesHere’s how to get the El Rubius skin in Fortnite with the most adorable back blingSeptember 17, 2024 | oneesports.ggOAll About the Rubius Skin in FortniteSeptember 17, 2024 | esports.netETwitch star Rubius is giving Fortnite players a good reason to buy his skinSeptember 17, 2024 | dexerto.comDFortnite Fans Only Want One Thing from the Rubius SkinSeptember 17, 2024 | msn.comHow to get the Rubius Icon Series skin in FortniteSeptember 16, 2024 | dexerto.comDHow to Get the Exclusive Rubius Fortnite DropSeptember 15, 2024 | msn.comRubius teases potential Fortnite Icon Series skin in cryptic YouTube videoAugust 4, 2024 | dexerto.comD‘Expats’ Star Ruby Ruiz to Lead James J. Robinson’s Directorial Debut ‘First Light’ (EXCLUSIVE)April 26, 2024 | yahoo.comVacant Rubius property generating interest after 1 year on marketApril 18, 2024 | pbn.comPSensorium Therapeutics Appoints Sam Rasty as Chief Business OfficerApril 17, 2024 | citizentribune.comCVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'March 11, 2024 | bizjournals.comRubius Therapeutics Inc RUBYNovember 5, 2023 | morningstar.comM‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sectorOctober 16, 2023 | bostonglobe.comBRuby Dunne Biography & MoviesSeptember 22, 2023 | tribute.caTParenting Vlogger Ruby Franke Held Without Bail on Child Abuse ChargesSeptember 14, 2023 | oxygen.comOYouTuber mom Ruby Franke arrested and charged in child abuse investigation: What to knowSeptember 8, 2023 | today.comTRuby GonzalesAugust 21, 2023 | dailynews.comDRUBY - Rubius Therapeutics, Inc.August 2, 2023 | uk.finance.yahoo.comNorth American Morning Briefing: Alphabet, -2-July 25, 2023 | morningstar.comMRuby Rivera, 23ABCJune 30, 2023 | turnto23.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGTX, RUBY, GNFT, OYST, and OSIR Company DescriptionsGENFIT NASDAQ:GNFT$3.65 -0.10 (-2.67%) As of 07/11/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.MeiraGTx NASDAQ:MGTX$8.47 -0.15 (-1.74%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$8.52 +0.04 (+0.53%) As of 07/11/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Oyster Point Pharma NASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Rubius Therapeutics NASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
